CROHN’S DISEASE TREATMENT MARKET ANALYSIS

Crohn’s disease is a form of inflammatory bowel disease (IBD) that refers to a chronic inflammatory condition of the gastrointestinal tract causing inflammation in the digestive tract. The disease is confined to the colon of the large intestine and ileum of the small intestine.  The disease is often painful and debilitating and can lead to life-threatening complications in some cases. These complications may comprise of one or more factors that includes bowel obstruction, fistulas, ulcers, anal fissures, colon cancer, and other health issues. Crohn’s disease can be caused due to factors such as stress, diet, heredity and malfunctioning of the immune system. The disease can occur at any age. However, is likely to develop at young ages among majority of the individuals

Global crohn’s disease treatment market is estimated to be valued at US$ 10.92 billion in 2022 and is expected to exhibit a CAGR of 4.2% during the forecast period (2022-2030)

Figure 1.Global Crohn’s Disease Treatment Market Share (%), by Distribution Channel, 2022

To learn more about this report, request sample copy

Increasing prevalence of inflammatory bowel diseases is expected to drive growth of the crohn’s disease treatment market.

Factors such as increasing number of inflammatory bowel diseases (IBD) as well as rising number of patients suffering from Crohn’s disease is expected to significantly contribute to growth of the Crohn’s disease treatment market. For instance, according to an article published by the Journal BMC Gastroenterology, in May 2021, an illness-death model based on available data was established to project the future prevalence of IBD in Asia, and Iran in particular from 2017 to 2035. As per the results, in 2035, as compared to 2020, the study expected a 2.5-fold rise in prevalence for Iran with 69 thousand cases, a 2.3-fold increment for North Africa and the Middle East with 220 thousand cases, quadrupling of the prevalence for India with 2.2 million cases, a 1.5-fold increase for East Asia region with 4.5 million cases, and a 1.6-fold elevation in prevalence for high‐income Asia‐Pacific and Southeast Asia regions with 183 and 199 thousand cases respectively.

Figure 2.Global Crohn’s Disease Treatment Market Share (%), by Region, 2022

To learn more about this report, request sample copy

Increasing product launches and development of new and effective therapy options to cure the symptoms of the crohn’s disease are expected to drive market growth during the forecast period.

Development of new and effective therapy options to cure the symptoms of crohn’s disease is also a vital factor contributing to growth of Crohn’s disease treatment market. For instance, researchers from University of Washington Medicine at the Crohn's & Colitis Congress held in January 2018 presented a study that developed an antibiotic, which showed four fold better response on the inflammation of intestine among patients suffering with Crohn’s disease as compared to the existing therapies available in market.

Global Crohn’s Disease Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic had a significant impact on the crohn’s disease treatment market, owing to the disease exacerbation due to the COVID-19 pandemic. For instance, according to an article published by the Frontiers Media S.A. in December 2021, a questionnaire survey on patients with Inflammatory Bowel Disease (IBD) from June 16 to August 21, 2020 during their regular follow-up at a hospital in Japan was carried out. According to the results, 241 patients with ulcerative colitis (UC) and 210 with Crohn's disease (CD) completed the survey, of which 82 (34%) and 97 (46%) patients, respectively, reported disease exacerbation within 2 months after the lockdown. The results suggest that changes in daily life and stress status due to the pandemic and lockdown measures were associated with worsening IBD symptoms, especially in young patients.

Global Crohn’s Disease Treatment Market: Key Developments

On June 17, 2022, AbbVie Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).

In March 2022, Tiziana Life Sciences, a biotechnology company, had commenced a Phase Ib clinical trial of oral enteric-coated capsules of foralumab (TZLS-401), a monoclonal antibody (mAb), in mild-to-moderate Crohn’s disease (CD) patients.

Global Crohn’s Disease Treatment Market: Restraint

The major factors that hinder growth of the global crohn’s disease treatment market include low awareness about the available treatment options among people and high cost of the drugs used in the treatment of crohn’s disease. For instance, a 2019 study from the Crohn’s & Colitis Foundation found that people with Crohn’s disease typically incur about US$ 30,000 in care costs in the year of their initial diagnosis

Key Players

Major players operating in the global crohn’s disease treatment market include AbbVie Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, Mylan N.V., Amgen Inc., and AstraZeneca.